Cancer treatment has been commercialised and is no longer primarily focused on helping patients live longer, according to a group of over 30 medics and academics from around the world.
Writing in The Lancet, a medical journal, the doctors lamented “a shift over the past few decades from predominantly publicly funded clinical trials designed to answer questions important to patients, to industry-funded trials which aim to achieve regulatory approval or commercial advantage.”
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
